Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- PODIUM PRESENTATION AT THE AMERICAN HEAD AND NECK SOCIETY (AHNS) 12TH INTERNATIONAL CONFERENCE ON HEAD AND NECK CANCER TO REPORT RESULTS FROM A STUDY OF ALPHA DART IN COMBINATION WITH PEMBROLIZUMAB (KEYTRUDA) IN ELDERLY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - - AMONG ALL NINE EVALUABLE PATIENTS, THE COMBINATION PRODUCED A SYSTEMIC OBJECTIVE RESPONSE RATE (ORR) OF 100%, INCLUDING FOUR COMPLETE RESPONSES AND FIVE PARTIAL RESPONSES, COMPARED TO JUST 19% ORR FROM HISTORICAL BENCHMARKS FOR PEMBROLIZUMAB MONOTHERAPY IN THIS SETTING - - MEDIAN OVERALL SURVIVAL OF 18.2 MONTHS AND MEDIAN PROGRESSION-FREE SURVIVAL OF 5.4 MONTHS COMPARE FAVORABLY WITH HISTORICAL BENCHMARKS FOR PEMBROLIZUMAB MONOTHERAPY IN THIS SETTING OF 12.3 MONTHS AND 3.2 MONTHS, RESPECTIVELY - - NO ALPHA DART-ASSOCIATED SERIOUS ADVERSE EVENTS WERE OBSERVED; THE ONLY TWO ALPHA DART-ASSOCIATED ADVERSE EVENTS WERE GRADE 1 (MILD) - - RESULTS BUILD ON FOUNDATION OF ALPHA DART MONOTHERAPY DATA IN HEAD AND NECK CANCER, AND LEND SUPPORT TO ALPHA TAU'S ONGOING CLINICAL STRATEGY EXPLORING THE COMBINATION APPROACH, WHICH THE COMPANY CONTINUES TO DISCUSS WITH THE U.S. FDA - - TRIAL RECRUITMENT IS NOW COMPLETE, HAVING MET THE PRE-SPECIFIED SUCCESS CRITERION OF ITS SIMON TWO-STAGE ADAPTIVE DESIGN: MORE THAN SIX PATIENTS RESPONDING TO THE TREATMENT - JERUSALEM, JULY 21, 2026 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (ALPHA TAU OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, TODAY ANNOUNCED POSITIVE RESULTS FROM A CLINICAL STUDY EVALUATING ALPHA DART IN COMBINATION WITH PEMBROLIZUMAB (KEYTRUDA) IN ELDERLY PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), IN WHICH THE COMBINATION PRODUCED A 100% OBJECTIVE RESPONSE RATE AND A MEDIAN OVERALL SURVIVAL OF 18.2 MONTHS AMONG EVALUABLE PATIENTS.

ALPHA TAU REPORTS POSITIVE DATA DEMONSTRATING 100% OBJECTIVE RESPONSE RATE AND 18.2-MONTH MEDIAN OVERALL SURVIVAL WITH ALPHA DART IN COMBINATION WITH PEMBROLIZUMAB IN LOCALLY ADVANCED OR METASTATIC HEAD AND NECK CANCER, SURPASSING THE STUDY'S PRE-SPECIFIED THRESHOLD FOR SUCCESS

ALPHA TAU SUCCESSFULLY TREATS FIRST IMMUNOCOMPROMISED PATIENT WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITS ADMIRE STUDY AT BANNER MD ANDERSON

ALPHA TAU SUCCESSFULLY TREATS FIRST IMMUNOCOMPROMISED PATIENT WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA IN ITS ADMIRE STUDY AT BANNER MD ANDERSON CANCER CENTER

ALPHA TAU SUCCESSFULLY TREATS FIRST RECURRENT GLIOBLASTOMA PATIENT OUTSIDE OF THE UNITED STATES WITH ALPHA DART AT HADASSAH MEDICAL CENTER IN ISRAEL

ALPHA TAU SUCCESSFULLY TREATS FIRST RECURRENT GLIOBLASTOMA PATIENT OUTSIDE OF THE UNITED STATES WITH ALPHA DART AT HADASSAH UNIVERSITY MEDICAL CENTER IN ISRAEL

ALPHA TAU RECEIVES FDA CLEARANCE TO COMPLETE ENROLLMENT IN REGAIN TRIAL AND ADD TWO U.S. SITES; EARLY INTERIM RESULTS SHOWED 100% LOCAL DISEASE CONTROL

ALPHA TAU RECEIVES FDA CLEARANCE TO COMPLETE ENROLLMENT IN REGAIN RECURRENT GLIOBLASTOMA TRIAL AND ADD TWO U.S. CLINICAL SITES; EARLY INTERIM RESULTS SHOWED 100% LOCAL DISEASE CONTROL

- JOINT PARTNERSHIP LEVERAGES ALPHA TAU'S HIGHLY POTENT, LOCALIZED ALPHA-RADIATION TECHNOLOGY AND TOLMAR'S COMMERCIAL LEADERSHIP TO TRANSFORM THE U.S. URO-ONCOLOGY LANDSCAPE - COLLABORATION ELEVATES PROSTATE CANCER AS A CORE STRATEGIC FOCUS, BACKED BY TOLMAR'S INITIAL $15M MANUFACTURING INVESTMENT, $20M EQUITY INFUSION AT $11.99 PER SHARE (25% PREMIUM TO 30-DAY VWAP), AND UP TO $161.5M IN CLINICAL, REGULATORY AND COMMERCIAL MILESTONES FOR THE FIRST INDICATION - AGREEMENT GRANTS TOLMAR EXCLUSIVE U.S. COMMERCIALIZATION RIGHTS FOR PROSTATE CANCER, WITH AN OPTION TO EXPAND INTO BLADDER CANCER SUBJECT TO ADDITIONAL PAYMENTS - ALPHA TAU TO MANUFACTURE ALPHA DART FOR TOLMAR'S COMMERCIALIZATION, TO BE SOLD TO TOLMAR AT 60% OF THE ONWARD NET SALES PRICE, SUBJECT TO CERTAIN ADJUSTMENTS JERUSALEM AND DUBLIN, JUNE 03, 2026 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD . (NASDAQ: DRTS, DRTSW), DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, AND TOLMAR INTERNATIONAL LTD.

ALPHA TAU AND TOLMAR ANNOUNCE STRATEGIC COLLABORATION TO BRING ALPHA DART THERAPY TO U.S. UROLOGICAL CANCER PATIENTS

- RESULTS REINFORCE THE POTENTIAL FEASIBILITY AND SAFETY OF ALPHA DART AS A ONE-TIME, MINIMALLY INVASIVE INTRATUMORAL TREATMENT THAT FITS NATURALLY INTO THE PATIENT JOURNEY - - POOLED ANALYSIS OF THREE PROSPECTIVE PHASE I/II STUDIES IN LOCALLY ADVANCED OR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) DEMONSTRATES ENCOURAGING MEDIAN OVERALL SURVIVAL (MOS) ACROSS CHEMOTHERAPY-NAIVE, SECOND-LINE, AND HEAVILY PRETREATED PATIENT POPULATIONS - - PATIENTS TREATED WITH ALPHA DART AFTER 1ST LINE CHEMOTHERAPY REACHED MEDIAN OVERALL SURVIVAL (MOS) OF 11.2 AND 11.1 MONTHS IN METASTATIC AND LOCALLY ADVANCED DISEASE, RESPECTIVELY, FROM THE DATE OF TRIAL ENROLLMENT, COMPARED TO ~4 - 6 MONTHS FOR METASTATIC PATIENTS AND ~ 9 MONTHS FOR LOCALLY ADVANCED PATIENTS WITH SECOND-LINE CHEMOTHERAPY, BASED ON PUBLISHED HISTORICAL DATA - - FAVORABLE SAFETY PROFILE OBSERVED ACROSS THE ALPHA DART TRIALS, WITH TREATMENT-ASSOCIATED ADVERSE EVENTS REPORTED IN 36% OF SUBJECTS AND GRADE 3 EVENTS IN 9%, WITH NO TREATMENT-RELATED DEATHS AND NO CHRONIC TOXICITY; ALL GRADE 3 EVENTS RESOLVED - - FOLLOWING THESE STRONG SURVIVAL DATA, COMPANY NEXT TURNS TO ANTICIPATED COMPLETION OF RECRUITMENT IN THE MULTICENTER U.S. IMPACT PANCREATIC CANCER TRIAL, WHICH IS EXPLORING THE ABILITY OF ALPHA DART, IN COMBINATION WITH INITIATION OF FRONT-LINE CHEMOTHERAPY, TO DELIVER A POTENT AND FOCUSED LOCAL DOSE WITHOUT EXACERBATING THE HARSH SYSTEMIC SIDE EFFECTS OF STANDARD CHEMOTHERAPY - JERUSALEM, JUNE 01, 2026 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS, DRTSW) ("ALPHA TAU", OR THE "COMPANY"), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, TODAY ANNOUNCED POSITIVE OVERALL SURVIVAL AND SAFETY RESULTS FROM A POOLED ANALYSIS OF THREE PROSPECTIVE PHASE I/II CLINICAL STUDIES EVALUATING ENDOSCOPIC ULTRASOUND (EUS)-GUIDED INTRATUMORAL ALPHA DART TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC).

ALPHA TAU ANNOUNCES STRONG OVERALL SURVIVAL RESULTS FROM ALPHA DART PANCREATIC CANCER STUDIES PRESENTED AT 2026 ASCO ANNUAL MEETING

- GROUNDBREAKING INTERIM RESULTS FROM U.S. REGAIN TRIAL IN RECURRENT GLIOBLASTOMA DEMONSTRATE 100% LOCAL DISEASE CONTROL, 67% COMPLETE RESPONSE RATE, AND FAVORABLE SAFETY PROFILE - - COMPLETION OF PATIENT ENROLLMENT IN THE U.S. PIVOTAL RESTART TRIAL IN RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA, THE COMPANY'S FIRST U.S. PIVOTAL STUDY - - POOLED DATA FROM TWO PANCREATIC CANCER TRIALS PRESENTED AT DIGESTIVE DISEASE WEEK (DDW) 2026 DEMONSTRATED 100% LOCAL DISEASE CONTROL AND FAVORABLE SAFETY, THE FIRST ORAL PRESENTATION OF ALPHA DART  PANCREATIC DATA AT A PREMIER INTERNATIONAL GASTROENTEROLOGY CONFERENCE - - ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 2026 ASCO ANNUAL MEETING AND AT THE AHNS 12TH INTERNATIONAL CONFERENCE ON HEAD AND NECK CANCER, REFLECTING GROWING SCIENTIFIC RECOGNITION ACROSS MULTIPLE SOLID TUMOR INDICATIONS - - FDA APPROVAL OF AN IDE SUPPLEMENT TO EXPAND THE IMPACT PANCREATIC CANCER TRIAL TO PATIENTS RECEIVING GEMCITABINE WITH ABRAXANE  (NAB-PACLITAXEL) AND RECRUIT ADDITIONAL PATIENTS - - FIRST PATIENT SUCCESSFULLY TREATED FOR PANCREATIC CANCER IN EUROPE AT CHU GRENOBLE ALPES UNDER THE MULTICENTER ACAPELLA TRIAL IN FRANCE, AND FIRST PATIENT SUCCESSFULLY TREATED IN ITALY AT THE UNIVERSITY OF VERONA'S PANCREAS INSTITUTE - - CASH, CASH EQUIVALENTS, SHORT-TERM DEPOSITS AND RESTRICTED DEPOSITS BALANCE OF $80.2 MILLION PROVIDES RUNWAY FOR CONTINUED CLINICAL ADVANCEMENT AND COMMERCIAL PREPARATION - JERUSALEM, MAY 18, 2026 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (ALPHA TAU, OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, REPORTED FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDED A CORPORATE UPDATE.

ALPHA TAU ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

JERUSALEM, MAY 18, 2026 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, TODAY ANNOUNCED THAT CFO RAPHI LEVY WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN MAY 2026.

ALPHA TAU TO PARTICIPATE IN MAY INVESTOR CONFERENCES

- INTERIM RESULTS FROM THE FIRST THREE BRAIN CANCER PATIENTS TREATED; TWO OF WHOM DEMONSTRATED COMPLETE RESPONSE, WITH TOTAL DISAPPEARANCE OF ALL ENHANCING TUMOR LESIONS, PER MULTIPLE MRI SCANS SINCE TREATMENT -

ALPHA TAU ANNOUNCES GROUNDBREAKING INTERIM RESULTS FROM ITS U.S. ALPHA DART RECURRENT GLIOBLASTOMA TRIAL, WITH 100% LOCAL DISEASE CONTROL, 67% COMPLETE RESPONSE RATE, AND FAVORABLE SAFETY PROFILE OBSERVED - CONFERENCE CALL SCHEDULED FOR 8:30AM ET

JERUSALEM, MAY 08, 2026 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD . (NASDAQ: DRTS, DRTSW) ("ALPHA TAU", OR THE COMPANY), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL AND WEBCAST ON MONDAY, MAY 11, 2026 AT 8:30AM ET TO DISCUSS INTERIM CLINICAL DATA FROM THE FIRST THREE PATIENTS TREATED IN ITS U.S. TRIAL OF ALPHA DART FOR PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM), ALSO KNOWN AS THE REGAIN (RECURRENT GLIOBLASTOMA ALPHA-DART INTRATUMORAL THERAPY) TRIAL.

Alpha Tau Medical Ltd.

DRTS

Price

Financial Reports

No items found.

Press Releases

Alpha Tau Medical Ltd.

DRTS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

DRTS